Meanwhile, we also analyzed the CD4/CD8 ratios with those factors and observed that CD4/CD8 ratios were also strongly positively correlated with advanced tumor stages (p = 1.25 × 10−4), large tumor sizes (p = 0.04) and positive lymph node status (p = 5.58 × 10−4), but negatively correlated with RFS (p = 5.35 × 10−4) and OS (p = 4.92 × 10−3) (Table 1), suggesting that CD4/CD8 ratio is an useful and significant prognostic biomarker for assessing clinical outcomes of human breast cancer. The gene discussed is CD8A; the disease is breast cancer.